查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108352

幹細胞市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶和功能分類

Stem Cells Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球幹細胞市場預計將從2025年的168億美元成長到2035年的496億美元，CAGR為11.4%。幹細胞市場集中度適中，領先的生物技術公司、細胞療法開發商和研究機構著重拓展其再生醫學產品線和基於幹細胞的療法。市場成長的促進因素包括：再生醫學投資的增加、細胞療法臨床試驗的增加、在腫瘤學和神經病學領域的應用不斷拓展，以及幹細胞處理技術的持續進步。策略聯盟、臨床開發計畫和不斷擴大的生產能力持續加劇著市場競爭。例如，Bayer AG的完全子公司BlueRock Therapeutics於2025年1月宣布計劃啟動一項針對Vemdaneprocell的III期exPDite-2臨床試驗，Vemdaneprocell是一種用於臨床實驗多功能細胞衍生藥物。這將是首個針對此適應症的同種異體多功能細胞衍生療法的III 期臨床試驗，目的是向監管機構提交申請。

依類型分析市場，2025年成人幹細胞將主導幹細胞市場。這是因為成人幹細胞已擁有成熟的臨床應用，倫理爭議較少，可整體。成人幹細胞，尤其是造血幹細胞和間質幹細胞，廣泛用於治療血液系統疾病、免疫相關疾病、整形外科疾病以及組織再生。其已證實的安全性、不斷增加的核准療法以及在臨床研究中的廣泛應用，都鞏固了主導地位。對幹細胞移植投資的增加、再生醫學計畫的拓展以及成人幹細胞療法商業化的進展，都將繼續支持該領域在全球的主導地位。

市場區隔
類型 胚胎幹細胞、成體幹細胞、誘導性富潛能幹細胞、造血幹細胞、間質幹細胞、神經幹細胞、上皮幹細胞、其他
產品 細胞株、設備、耗材、其他
服務 細胞製備、細胞培養、冷凍保存、細胞增生、細胞分化、其他
技術 細胞療法、基因療法、組織工程、再生醫學、其他
組件 軟體、硬體、其他
用途 再生醫學、藥物發現與開發、毒理學測試、腫瘤學、神經病學、整形外科、循環系統、血液學、其他
過程 細胞分離、細胞增生、細胞冷凍保存、細胞分化、其他
最終用戶 研究機構、生技公司、製藥公司、醫院和診所、學術機構、其他
功能 用於治療、研究、其他

依應用領域分類，再生醫學領域預計將在預測期內實現最快成長，這主要得益於對修復或替代受損組織和器官的先進療法的需求不斷成長。基於幹細胞的再生醫學在神經系統疾病、心血管疾病、整形外科、糖尿病和自體免疫疾病的治療方面備受關注。臨床試驗的增加、細胞療法投資的擴大以及幹細胞工程技術的持續進步加速再生醫學的發展。此外，政府投入的增加、監管措施的支持以及個人化醫療的日益普及，預計也將顯著推動再生醫學領域在整個預測期內的成長。

區域概覽

2025年，北美憑藉其先進的生物技術生態系統、強大的研究基礎設施以及對再生醫學和細胞療法研發的大量投資，主導幹細胞市場的發展。該地區受惠於政府機構和私人投資者的優惠資助，以及許多大型生技公司、學術研究機構和專業的幹細胞治療中心。美國佔據最大的區域市場佔有率，這得益於其大量的幹細胞臨床試驗、細胞療法商業化的進展、完善的監管流程以及幹細胞技術在再生醫學、腫瘤學和個性化醫療領域的廣泛應用。加拿大則透過拓展研究合作和政府支持的生命科學計畫，為該地區的發展做出了貢獻。

預計亞太地區將在預測期內實現最快成長，這主要得益於醫療保健支出增加、生物技術研究拓展以及再生醫學投資的成長。中國、日本、韓國和印度等國家正透過政府資助、支持性監管改革和擴大臨床試驗活動，大幅提升其幹細胞研究能力。慢性病盛行率上升、生物製藥生產規模擴大以及先進細胞療法的日益普及，加速市場成長。此外，研究機構、生技公司和醫療服務提供者之間合作的加強，預計將進一步加速幹細胞技術在亞太地區的應用。

主要趨勢和促進因素

再生醫學和幹細胞療法的進展

幹細胞市場在再生醫學和目的是治療慢性病、退化性疾病疾病和罕見疾病的下一代幹細胞療法領域正經歷強勁成長。幹細胞工程、誘導性多功能幹細胞（iPS細胞）、基因編輯和組織工程領域的持續創新提高治療效果並拓展臨床應用。針對神經系統疾病、心血管疾病、整形外科和自體免疫疾病的臨床試驗需求不斷成長，加速商業化進程。此外，生物技術公司、研究機構和醫療服務提供者之間日益密切的合作促進創新，並推動幹細胞技術在研究和臨床實踐中的更廣泛應用。

增加對細胞療法研究和個人化醫療的投資

對再生醫學、細胞療法研究和個人化醫療的投資不斷增加，是幹細胞市場的主要驅動力。各國政府、生技公司、製藥公司和學術機構正大幅增加資金投入，用於開發針對癌症、神經系統疾病、心血管疾病和罕見遺傳疾病的創新幹細胞療法。慢性病盛行率的上升、臨床試驗活動的擴展以及對精準醫療需求的不斷成長，加速幹細胞技術的應用。此外，支持性的監管措施、幹細胞生產能力的提升以及先進細胞療法的商業化進程不斷推進，也為全球市場的持續成長創造了巨大機會。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 胚胎幹細胞
    • 成體幹細胞
    • 誘導性富潛能幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
    • 上皮幹細胞
    • 其他
  • 市場規模及預測：依產品分類
    • 細胞株
    • 裝置
    • 消耗品
    • 其他
  • 市場規模及預測：依服務分類
    • 細胞製備
    • 細胞培養
    • 冷凍保存
    • 細胞增殖
    • 細胞分化
    • 其他
  • 市場規模及預測：依技術分類
    • 細胞療法
    • 基因治療
    • 組織工程
    • 再生醫學
    • 其他
  • 市場規模及預測：依應用領域分類
    • 再生醫學
    • 藥物發現和藥物開發
    • 毒性測試
    • 腫瘤學
    • 神經病學
    • 整形外科
    • 循環系統
    • 血液學
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 研究機構
    • 生技公司
    • 製藥公司
    • 醫院和診所
    • 學術機構
    • 其他
  • 市場規模及預測：依製程分類
    • 細胞分離
    • 細胞增殖
    • 細胞冷凍保存
    • 細胞分化
    • 其他
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 其他
  • 市場規模及預測：依功能分類
    • 治療
    • 研究
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Thermo Fisher Scientific
  • Lonza Group
  • STEMCELL Technologies
  • CellGenix
  • Fujifilm Cellular Dynamics
  • Mesoblast
  • Athersys
  • Pluristem Therapeutics
  • BioTime
  • Cytori Therapeutics
  • Osiris Therapeutics
  • ReNeuron Group
  • StemCells Inc
  • Vericel Corporation
  • BrainStorm Cell Therapeutics
  • Gamida Cell
  • ViaCyte
  • Cynata Therapeutics
  • Astellas Pharma
  • Takara Bio

第9章 關於我們

簡介目錄
Product Code: GIS21224

The global Stem Cells Market is projected to grow from $16.8 billion in 2025 to $49.6 billion by 2035, at a compound annual growth rate (CAGR) of 11.4%. The Stem Cells Market is moderately consolidated, with leading biotechnology companies, cell therapy developers, and research organizations focusing on expanding regenerative medicine pipelines and stem cell-based therapeutics. Market growth is driven by increasing investments in regenerative medicine, rising clinical trials for cell therapies, expanding applications in oncology and neurology, and continuous advancements in stem cell processing technologies. Strategic collaborations, clinical development programs, and manufacturing capacity expansion continue to strengthen the competitive landscape. For instance, in January 2025, BlueRock Therapeutics, a wholly owned subsidiary of Bayer AG, announced plans to initiate the Phase III exPDite-2 clinical trial for bemdaneprocel, an investigational pluripotent stem cell-derived therapy for Parkinson's disease, marking the first registrational Phase III trial of an allogeneic pluripotent stem cell-derived therapy for this indication.

Based on Type, the Adult Stem Cells segment dominated the Stem Cells market in 2025 due to their established clinical use, fewer ethical concerns, and broad applicability across regenerative medicine and cell-based therapies. Adult stem cells, particularly hematopoietic and mesenchymal stem cells, are extensively used in the treatment of blood disorders, immune-related diseases, orthopedic conditions, and tissue regeneration. Their proven safety profile, increasing number of approved therapies, and widespread adoption in clinical research have strengthened market leadership. Rising investments in stem cell transplantation, expanding regenerative medicine programs, and growing commercialization of adult stem cell therapies continue to support the dominance of this segment globally.

Market Segmentation
TypeEmbryonic Stem Cells, Adult Stem Cells, Induced Pluripotent Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Epithelial Stem Cells, Others
ProductCell Lines, Instruments, Consumables, Others
ServicesCell Acquisition, Cell Culture, Cryopreservation, Cell Expansion, Cell Differentiation, Others
TechnologyCell Therapy, Gene Therapy, Tissue Engineering, Regenerative Medicine, Others
ComponentSoftware, Hardware, Others
ApplicationRegenerative Medicine, Drug Discovery and Development, Toxicology Studies, Oncology, Neurology, Orthopedics, Cardiology, Hematology, Others
ProcessCell Isolation, Cell Expansion, Cell Cryopreservation, Cell Differentiation, Others
End UserResearch Institutes, Biotechnology Companies, Pharmaceutical Companies, Hospitals and Clinics, Academic Institutions, Others
FunctionalityTherapeutic, Research, Others

Based on Application, the Regenerative Medicine segment is projected to register the fastest growth during the forecast period, driven by increasing demand for advanced therapies that restore or replace damaged tissues and organs. Stem cell-based regenerative medicine is gaining significant traction in the treatment of neurological disorders, cardiovascular diseases, orthopedic conditions, diabetes, and autoimmune diseases. Rising clinical trials, expanding investments in cell-based therapeutics, and continuous advancements in stem cell engineering are accelerating the development of regenerative therapies. Furthermore, growing government funding, supportive regulatory initiatives, and increasing adoption of personalized medicine are expected to significantly drive the growth of the regenerative medicine segment throughout the forecast period.

Geographical Overview

North America dominated the Stem Cells market in 2025, supported by its advanced biotechnology ecosystem, strong research infrastructure, and substantial investments in regenerative medicine and cell therapy development. The region benefits from the presence of leading biotechnology companies, academic research institutions, and specialized stem cell treatment centers, along with favorable funding from government agencies and private investors. The United States accounts for the largest regional share owing to its high volume of stem cell clinical trials, increasing commercialization of cell-based therapies, well-established regulatory pathways, and extensive adoption of stem cell technologies in regenerative medicine, oncology, and personalized medicine. Canada further contributes through growing research collaborations and government-supported life sciences initiatives.

Asia-Pacific is projected to register the fastest growth during the forecast period, driven by increasing healthcare expenditure, expanding biotechnology research, and growing investments in regenerative medicine. Countries such as China, Japan, South Korea, and India are significantly strengthening their stem cell research capabilities through government funding, supportive regulatory reforms, and increasing clinical trial activities. Rising prevalence of chronic diseases, expanding biopharmaceutical manufacturing, and growing adoption of advanced cell-based therapies are accelerating market growth. Furthermore, increasing collaborations between research institutes, biotechnology companies, and healthcare providers are expected to further boost the adoption of stem cell technologies across the Asia-Pacific region.

Key Trends and Drivers

Advancements in Regenerative Medicine and Stem Cell-Based Therapies:

The Stem Cells market is witnessing a strong trend toward the advancement of regenerative medicine and next-generation stem cell-based therapies for the treatment of chronic, degenerative, and rare diseases. Continuous innovations in stem cell engineering, induced pluripotent stem cells (iPSCs), gene editing, and tissue engineering are improving therapeutic efficacy and expanding clinical applications. Increasing numbers of clinical trials targeting neurological, cardiovascular, orthopedic, and autoimmune disorders are accelerating commercialization. In addition, growing collaborations between biotechnology companies, research institutes, and healthcare providers are fostering innovation and supporting the broader adoption of stem cell technologies across research and clinical settings.

Rising Investments in Cell Therapy Research and Personalized Medicine:

Growing investments in regenerative medicine, cell therapy research, and personalized medicine are major drivers of the Stem Cells market. Governments, biotechnology companies, pharmaceutical firms, and academic institutions are significantly increasing funding to develop innovative stem cell therapies for cancer, neurological disorders, cardiovascular diseases, and rare genetic conditions. The rising prevalence of chronic diseases, expanding clinical trial activity, and increasing demand for precision medicine are accelerating the adoption of stem cell technologies. Furthermore, supportive regulatory initiatives, improving stem cell manufacturing capabilities, and expanding commercialization of advanced cell therapies are creating significant opportunities for sustained market growth worldwide.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Embryonic Stem Cells
    • 4.1.2 Adult Stem Cells
    • 4.1.3 Induced Pluripotent Stem Cells
    • 4.1.4 Hematopoietic Stem Cells
    • 4.1.5 Mesenchymal Stem Cells
    • 4.1.6 Neural Stem Cells
    • 4.1.7 Epithelial Stem Cells
    • 4.1.8 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Acquisition
    • 4.3.2 Cell Culture
    • 4.3.3 Cryopreservation
    • 4.3.4 Cell Expansion
    • 4.3.5 Cell Differentiation
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Therapy
    • 4.4.2 Gene Therapy
    • 4.4.3 Tissue Engineering
    • 4.4.4 Regenerative Medicine
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Regenerative Medicine
    • 4.5.2 Drug Discovery and Development
    • 4.5.3 Toxicology Studies
    • 4.5.4 Oncology
    • 4.5.5 Neurology
    • 4.5.6 Orthopedics
    • 4.5.7 Cardiology
    • 4.5.8 Hematology
    • 4.5.9 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Research Institutes
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Pharmaceutical Companies
    • 4.6.4 Hospitals and Clinics
    • 4.6.5 Academic Institutions
    • 4.6.6 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Cell Isolation
    • 4.7.2 Cell Expansion
    • 4.7.3 Cell Cryopreservation
    • 4.7.4 Cell Differentiation
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Software
    • 4.8.2 Hardware
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Therapeutic
    • 4.9.2 Research
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Thermo Fisher Scientific
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza Group
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 STEMCELL Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 CellGenix
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fujifilm Cellular Dynamics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Mesoblast
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Athersys
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Pluristem Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BioTime
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cytori Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Osiris Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ReNeuron Group
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 StemCells Inc
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Vericel Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 BrainStorm Cell Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gamida Cell
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 ViaCyte
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cynata Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Astellas Pharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Takara Bio
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us